Advertisement

New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules

  • Mario Sánchez-BorgesEmail author
  • Arnaldo Capriles-Hulett
  • Jose Antonio Ortega-Martell
  • Ignacio Ansotegui Zubeldia
Allergic Skin Diseases (Luz Fonacier and Andreas Wollenberg, Section Editors)
  • 214 Downloads
Part of the following topical collections:
  1. Topical Collection on Allergic Skin Diseases

Abstract

Purpose of Review

An update on new therapies currently approved or potentially useful in the future for the management of patients suffering moderate-to-severe atopic dermatitis.

Recent Findings

New pathogenic mechanisms involved in atopic dermatitis have permitted to propose novel therapeutic approaches devised to control the inflammatory process observed in involved cutaneous tissues by neutralizing mediators, cytokines, and their receptors.

Summary

Recent research findings have disclosed important and previously unrecognized pathogenic mechanisms that have resulted in innovative targeted therapies, such as dupilumab, and potentially other biologicals and small molecules. Further studies should permit the sub-classification of patients according to the relevance of different mediators and inflammatory cells. It can be concluded that the treatment of atopic dermatitis has entered into the era of personalized/precision medicine.

Keywords

Atopic dermatitis Biologicals Dupilumab Eczema Small molecules Treatment 

Abbreviations

IGA

Investigator Global Assessment

EASI

Eczema Area and Severity Index

TSLP

Thymus stromal lymphopoietin

ILC

Innate lymphoid cell

SCORAD

Scoring of Atopic Dermatitis

Notes

Funding

Investigator’s funds.

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Asher I, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood. ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–43.CrossRefGoogle Scholar
  2. 2.
    Hanifin JM, Reed ML, Eczema P. Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18:82–91.CrossRefGoogle Scholar
  3. 3.
    Silverberg JL, Simpson EL. Associations of childhood eczema severity: a U.S. population-based study. Dermatitis. 2014;25:107–11.CrossRefGoogle Scholar
  4. 4.
    Odhiambo MM, Williams HC, Clayton TO, Robertson CF, Asher MI, the ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124:1251–8.CrossRefGoogle Scholar
  5. 5.
    • Eichenfeld LF, Ahluwalia J, Waldman A, Borok J, Udkoff JP, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139:S49–57. A comparative review of the management of AD in different world settings.CrossRefGoogle Scholar
  6. 6.
    •• Bieber T, D’Erme AM J, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139:S58–64. An important proposal to classify AD into subtypes that would give orientation on best personalized approaches to the treatment.CrossRefGoogle Scholar
  7. 7.
    Brunner PM, Silverberg JL, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137:18–25.CrossRefGoogle Scholar
  8. 8.
    Gupta J, Johansson E, Bernstein JA, Chakraborty R, Khurana Hershey GK, Rothenberg ME, et al. Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry. J Allergy Clin Immunol. 2016;138:676–99.CrossRefGoogle Scholar
  9. 9.
    • Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336–49. A comprehensive review on the pathogenic pathways involved in AD.CrossRefGoogle Scholar
  10. 10.
    Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy, Asthma Immunol Res. 2018;10(3):207–15.CrossRefGoogle Scholar
  11. 11.
    Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278:116–30.CrossRefGoogle Scholar
  12. 12.
    Rodrıguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123:1361–70.CrossRefGoogle Scholar
  13. 13.
    Gao PS, Rafaels NM, Mu D, Hand T, Murray T, Boguniewicz M, et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010;125:1403–7.CrossRefGoogle Scholar
  14. 14.
    Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139:S65–76.CrossRefGoogle Scholar
  15. 15.
    • Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77:623–33. An overview of the indications to use immune modulators and biologics in severe AD.CrossRefGoogle Scholar
  16. 16.
    Taleb A, Seneschal J, Mossalayi MD. Biologics in atopic dermatitis. J Dutch Dermatol Ges. 2012;10:174–8.Google Scholar
  17. 17.
    • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5:1477–87. An update on the use of biologics in AD.CrossRefGoogle Scholar
  18. 18.
    Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–43.CrossRefGoogle Scholar
  19. 19.
    Klonowska J, Gleń J, Nowicki RJ, Trzeciak M. New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets. Int J Mol Sci. 2018;19:3086.CrossRefGoogle Scholar
  20. 20.
    • Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9. Important because it supports the efficacy of dupilumab in AD.CrossRefGoogle Scholar
  21. 21.
    • Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48 Brunner PM, JACI 2017. A review of main studies leading to the approval of dupilumab for AD. CrossRefGoogle Scholar
  22. 22.
    Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293–300.CrossRefGoogle Scholar
  23. 23.
    Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, et al. Alopecia areata profiling shows TH1, TH2, and IL-3 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136:1277–87.CrossRefGoogle Scholar
  24. 24.
    Zaghi D, Krueger GG, Callis DK. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol. 2012;11(2):160–7.PubMedGoogle Scholar
  25. 25.
    Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28–35.CrossRefGoogle Scholar
  26. 26.
    Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol. 2012;130:1335–43.e5.CrossRefGoogle Scholar
  27. 27.
    Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295:459–64.CrossRefGoogle Scholar
  28. 28.
    Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863–871.e11.CrossRefGoogle Scholar
  29. 29.
    Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2018.  https://doi.org/10.1016/j.jaci.2018.05.029.
  30. 30.
    Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014;20:60–5.CrossRefGoogle Scholar
  31. 31.
    Nakajima S, Kitoh A, Egawa G, Natsuaki Y, Nakamizo S, Moniaga CS, et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Investig Dermatol. 2014;134:2122–30.CrossRefGoogle Scholar
  32. 32.
    Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625–30.CrossRefGoogle Scholar
  33. 33.
    Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman SC, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361–70.CrossRefGoogle Scholar
  34. 34.
    Thaci D, Contanstin MM, Rojkovich B, Timmis H, Klöpfer P, et al. MOR106, anti-IL-17C mAb, a potential new approach for treatment of moderate-to-severe atopic dermatitis. Phase 1 study. In Proceedings of the American Academy of Dermatology Annual Meeting, Orlando, FL, USA, 3–7 March 2017.Google Scholar
  35. 35.
    Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017;376:826–35.CrossRefGoogle Scholar
  36. 36.
    Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121–1130.e7.CrossRefGoogle Scholar
  37. 37.
    Miller A. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22.CrossRefGoogle Scholar
  38. 38.
    Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, Lehtimäki S, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012 May;132(5):1392–400.CrossRefGoogle Scholar
  39. 39.
    Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–50.CrossRefGoogle Scholar
  40. 40.
    Du MY, Fu HY, Li DN, Qiao Y, Wang QW, Liu W. The expression and regulation of interleukin-33 in human epidermal keratinocytes: a new mediator of atopic dermatitis and its possible signaling pathway. J Interf Cytokine Res. 2016;36:552–62.CrossRefGoogle Scholar
  41. 41.
    Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol. 2014 May;70(5):882–8.CrossRefGoogle Scholar
  42. 42.
    Taniguchi K, Yamamoto S, Hitomi E, Inada Y, Suyama Y, Sugioka T, et al. Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol. 2013;23:428–34.PubMedGoogle Scholar
  43. 43.
    Peng G, Mu Z, Cui L, Liu P, Wang Y, Wu W, et al. Anti-IL-33 antibody has a therapeutic effect in an atopic dermatitis murine model induced by 2, 4-dinitrochlorobenzene. Inflammation. 2018;41:154–63.CrossRefGoogle Scholar
  44. 44.
    Nygaard U, Hvid M, Johansen C, Buchner M, Fölster-Holst R, Deleuran M, et al. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30:1930–8.PubMedGoogle Scholar
  45. 45.
    Liu YJ. Thymic stromal lymphopoietin (TSLP): master switch for allergic inflammation. J Exp Med. 2006;203:269–73.CrossRefGoogle Scholar
  46. 46.
    Sano Y, Masuda K, Tamagawa-Mineoka R, Matsunaka H, Murakami Y, Yamashita R, et al. Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin Exp Immunol. 2013;171:330–7.CrossRefGoogle Scholar
  47. 47.
    Wang IJ, Wu LS, Lockett GA, Karmaus WJ. TSLP polymorphisms, allergen exposures, and the risk of atopic disorders in children. Ann Allergy Asthma Immunol. 2016;116:139–45.CrossRefGoogle Scholar
  48. 48.
    Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2018.  https://doi.org/10.1016/j.jaad.2018.11.059.
  49. 49.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.e6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mario Sánchez-Borges
    • 1
    • 2
    Email author
  • Arnaldo Capriles-Hulett
    • 1
  • Jose Antonio Ortega-Martell
    • 3
  • Ignacio Ansotegui Zubeldia
    • 4
  1. 1.Allergy and Clinical Immunology DepartmentCentro Médico Docente La TrinidadCaracasVenezuela
  2. 2.Clínica El AvilaCaracasVenezuela
  3. 3.School of MedicineAutonomous University of Hidalgo StatePachucaMexico
  4. 4.Department of Allergy and ImmunologyHospital QuironsaludBilbaoSpain

Personalised recommendations